Citadel Advisors
FLGT icon

Citadel Advisors’s Fulgent Genetics FLGT Stock Holding History

Citadel Advisors’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$842K Sell
52,948
-190,176
-78% -$4.13M ﹤0.01% 8055
2025
Q4 		$6.39M Sell
243,124
-128,352
-35% -$3.33M ﹤0.01% 3904
2025
Q3 		$8.4M Sell
371,476
-232,177
-38% -$4.78M ﹤0.01% 3522
2025
Q2 		$12M Buy
603,653
+167,911
+39% +$3.27M ﹤0.01% 2776
2025
Q1 		$7.36M Buy
435,742
+209,123
+92% +$3.56M ﹤0.01% 3298
2024
Q4 		$4.19M Sell
226,619
-76,299
-25% -$1.49M ﹤0.01% 4257
2024
Q3 		$6.58M Buy
302,918
+116,683
+63% +$2.61M ﹤0.01% 3511
2024
Q2 		$3.65M Buy
186,235
+73,796
+66% +$1.54M ﹤0.01% 4258
2024
Q1 		$2.44M Sell
112,439
-10,441
-8% -$259K ﹤0.01% 5141
2023
Q4 		$3.55M Sell
122,880
-70,136
-36% -$1.88M ﹤0.01% 4348
2023
Q3 		$5.16M Sell
193,016
-271,406
-58% -$9.27M ﹤0.01% 3598
2023
Q2 		$17.2M Buy
464,422
+166,247
+56% +$5.79M ﹤0.01% 2040
2023
Q1 		$9.31M Buy
298,175
+240,849
+420% +$7.75M ﹤0.01% 2904
2022
Q4 		$1.71M Sell
57,326
-107,467
-65% -$3.85M ﹤0.01% 5769
2022
Q3 		$6.28M Buy
164,793
+42,057
+34% +$2.11M ﹤0.01% 3509
2022
Q2 		$6.69M Buy
122,736
+61,468
+100% +$3.38M ﹤0.01% 3280
2022
Q1 		$3.82M Sell
61,268
-167,624
-73% -$11M ﹤0.01% 4696
2021
Q4 		$23M Sell
228,892
-28,528
-11% -$2.51M ﹤0.01% 1866
2021
Q3 		$23.2M Buy
257,420
+243,672
+1,772% +$22.1M ﹤0.01% 1835
2021
Q2 		$1.27M Sell
13,748
-144,784
-91% -$11.6M ﹤0.01% 7729
2021
Q1 		$15.3M Buy
158,532
+146,623
+1,231% +$15.1M ﹤0.01% 2339
2020
Q4 		$620K Buy
11,909
+1,723
+17% +$72K ﹤0.01% 7745
2020
Q3 		$408K Buy
+10,186
New +$319K ﹤0.01% 7626

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Citadel Advisors's FLGT Position: Q1 2026 in Review

Citadel Advisors reduced its Fulgent Genetics (FLGT) stake by 78% in Q1 2026, selling an estimated $4.13M and leaving 52,948 shares worth $842K. The position accounts for ﹤0.01% of the portfolio, ranked #8055.

Citadel Advisors first reported a position in FLGT in Q3 2020 and has held it in 23 quarters since. The position peaked at $23.2M in Q3 2021. 157 funds tracked by Wall St. Rank hold FLGT as of Q1 2026.

  • Citadel Advisors held 52,948 shares of Fulgent Genetics worth $842K as of Q1 2026.
  • Citadel Advisors sold 190,176 Fulgent Genetics shares in Q1 2026, an estimated $4.13M.
  • Fulgent Genetics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #8055 holding.
  • Citadel Advisors first reported a position in Fulgent Genetics in Q3 2020 and has held it in 23 quarters since.
  • Citadel Advisors's Fulgent Genetics position peaked at $23.2M in Q3 2021.
  • 157 funds tracked by Wall St. Rank held Fulgent Genetics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.